{"id":"721f8de3-9338-5619-ab65-e30ddf8aa40c","stable_key":"7484635e-cc8f-5cd6-a978-6dc5775a7db5:berberine-nitroreductase-marker","predicate":"correlates_with","statement":"Human fecal nitroreductase activity correlated positively with blood berberine, with reported r=0.703.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"547576f1-e13c-5588-9027-c3b1fe5a5a23","mechanism_event_label":"Microbial processing may help explain why exposure differs between people.","subject":{"id":"d5d9b5d9-99bf-58cf-ba7a-d4346547b886","slug":"fecal-nitroreductase-activity","display_name":"Fecal bacterial nitroreductase activity","entity_type_key":"cellular_process"},"object":{"id":"ab144e4b-d924-5686-873d-64c5e16fb13d","slug":"berberine-plasma-exposure","display_name":"Plasma berberine exposure","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"547576f1-e13c-5588-9027-c3b1fe5a5a23","stable_key":"7484635e-cc8f-5cd6-a978-6dc5775a7db5:berberine-nitroreductase-marker-event","event_type":"observed_intervention","label":"Microbial processing may help explain why exposure differs between people.","description":"Human fecal nitroreductase activity correlated positively with blood berberine, with reported r=0.703.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"d5d9b5d9-99bf-58cf-ba7a-d4346547b886","slug":"fecal-nitroreductase-activity","display_name":"Fecal bacterial nitroreductase activity","entity_type_key":"cellular_process"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"ab144e4b-d924-5686-873d-64c5e16fb13d","slug":"berberine-plasma-exposure","display_name":"Plasma berberine exposure","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/berberine-research/28744326.abstract.txt\", \"locator\": \"Primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"d386d585993ca345f94fd99c5fbe0b209f6000fc10852db0a88621c03fc77830\", \"start_char\": 0, \"end_char\": 1247, \"text_sha256\": \"d386d585993ca345f94fd99c5fbe0b209f6000fc10852db0a88621c03fc77830\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Dietary animal experiments and human observational pharmacokinetic comparison","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"High-fat diet in hamsters; oral berberine in animal and human arms","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Human association does not validate fecal nitroreductase as a clinical dosing test. Diet, disease and microbial composition are potential covariates.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Berberine research collection; topical membership is not evidence of a direct dietary effect.","comparator":null,"unit":null,"notes":"","entity":{"slug":"berberine","display_name":"Berberine","entity_type_key":"small_molecule"}},{"dimension":"organism","value_text":"Hamsters, human hyperlipidemia patients and healthy participants","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"Microbial processing may help explain why exposure differs between people.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[berberine-p28744326] Gut Microbiota-Mediated Personalized Treatment of Hyperlipidemia Using Berberine. (2017). https://pubmed.ncbi.nlm.nih.gov/28744326/ DOI: 10.7150/thno.18290","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Fecal enzyme activity and blood berberine","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"6e03b7db-c0de-5922-bb78-b853cad21b7c","evidence_kind":"source_excerpt","locator":"Lines 194-205","start_line":194,"end_line":205,"excerpt":"### berberine-nitroreductase-marker\nHuman fecal nitroreductase activity correlated positively with blood berberine, with reported r=0.703.\nCondition category: normal\nnutrient_topic: Berberine research collection; topical membership is not evidence of a direct dietary effect.\nplain_language: Microbial processing may help explain why exposure differs between people.\norganism: Hamsters, human hyperlipidemia patients and healthy participants\ntissue_or_cell_type: Fecal enzyme activity and blood berberine\nexperimental_model: Dietary animal experiments and human observational pharmacokinetic comparison\nlimitations: Human association does not validate fecal nitroreductase as a clinical dosing test. Diet, disease and microbial composition are potential covariates.\nexposure: High-fat diet in hamsters; oral berberine in animal and human arms\nevidence_span: {\"source_cache\": \"artifacts/berberine-research/28744326.abstract.txt\", \"locator\": \"Primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"d386d585993ca345f94fd99c5fbe0b209f6000fc10852db0a88621c03fc77830\", \"start_char\": 0, \"end_char\": 1247, \"text_sha256\": \"d386d585993ca345f94fd99c5fbe0b209f6000fc10852db0a88621c03fc77830\"}\n[berberine-p28744326] Gut Microbiota-Mediated Personalized Treatment of Hyperlipidemia Using Berberine. (2017). https://pubmed.ncbi.nlm.nih.gov/28744326/ DOI: 10.7150/thno.18290","model_system":"Dietary animal experiments and human observational pharmacokinetic comparison","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [berberine-p28744326] Gut Microbiota-Mediated Personalized Treatment of Hyperlipidemia Using Berberine. (2017). https://pubmed.ncbi.nlm.nih.gov/28744326/ DOI: 10.7150/thno.18290","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"9bb61e1d-e5cf-5b05-a9ca-409291f7a313","stable_key":"import-7484635e-cc8f-5cd6-a978-6dc5775a7db5","title":"Berberine: metabolism, nutrient connections and drug interactions (2026-09-17)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"2f376a035ae79c93e62e2ea4a8d5385643bf16553f108d12b6a80c89e6d41f4c","revision_id":"2a099429-1c4a-55be-aa2c-0565d08bda80","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}